Celsion Corp (CLSN)

1.21
NASDAQ : Health Care
Prev Close 1.23
Day Low/High 1.21 / 1.25
52 Wk Low/High 1.04 / 2.63
Avg Volume 66.60K
Exchange NASDAQ
Shares Outstanding 23.44M
Market Cap 28.83M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Celsion Announces Presentation Of OVATION Study Clinical Trial Design At Upcoming ASCO 2016 Meeting

Celsion Announces Presentation Of OVATION Study Clinical Trial Design At Upcoming ASCO 2016 Meeting

Company Expects to Report Data from Second Cohort of the OVATION Study by Mid-Year, Followed by Translational Data for the First Two Cohorts in the Third Quarter

Celsion Corporation Announces Positive Data From The First Cohort Of Patients In The OVATION Study

Celsion Corporation Announces Positive Data From The First Cohort Of Patients In The OVATION Study

GEN-1 Immunotherapy Together with Standard Chemotherapy in First Line Ovarian Cancer Patients Demonstrates Impressive Outcomes

Celsion Corporation Announces Enrollment Of First Patient In The OPTIMA Study In China

Celsion Corporation Announces Enrollment Of First Patient In The OPTIMA Study In China

With China FDA's Approval of Celsion's Phase III Study in First Line Primary Liver Cancer, the Trial is Now Enrolling Patients in 13 Countries World-wide

Celsion Presents Compelling Data At AACR 2016 Demonstrating Synergistic Anti-Cancer Effect Of GEN-1 IL-12 Immunotherapy Plus Avastin® And Doxil®

Celsion Presents Compelling Data At AACR 2016 Demonstrating Synergistic Anti-Cancer Effect Of GEN-1 IL-12 Immunotherapy Plus Avastin® And Doxil®

Preclinical Studies Demonstrate a 98% Reduction in Tumor Burden Compared to Control

Celsion Announces Presentation Of Preclinical Data For GEN-1 IL-12 Immunotherapy In Combination With Avastin® And Doxil® At The AACR Annual Meeting 2016

Celsion Announces Presentation Of Preclinical Data For GEN-1 IL-12 Immunotherapy In Combination With Avastin® And Doxil® At The AACR Annual Meeting 2016

Preclinical Studies Demonstrate Statistically Significant Synergistic Anti-Cancer Effects when GEN-1 is combined with Avastin® and Doxil®

Celsion Corporation Announces Launch Of The OPTIMA Study In China

Celsion Corporation Announces Launch Of The OPTIMA Study In China

Conference Attended by 20 Principal Investigators and Research Teams Representing Major Centers throughout China and Hong Kong

Celsion Corporation Announces Issuance Of Key U.S. Patent Covering Its Novel TheraSilence™ RNA Program

Celsion Corporation Announces Issuance Of Key U.S. Patent Covering Its Novel TheraSilence™ RNA Program

Company's First-in-Class Technology Enables Lung-Specific Delivery of RNA with a Development Focus on Lung Cancer

Celsion Corporation Highlights Recent Pipeline Developments For Its GEN-1 Immunotherapy Program And Provides Business Update

Celsion Corporation Highlights Recent Pipeline Developments For Its GEN-1 Immunotherapy Program And Provides Business Update

Enrollment of First Cohort Completed in the OVATION Study - A Phase 1b Trial to Assess GEN-1 IL-12 Immunotherapy in Combination with Neo-Adjuvant Therapies in Newly Diagnosed Ovarian Cancer Patients

Celsion Reports Translational Research Data From Its Phase 1b Study Of GEN-1 Immunotherapy In Recurrent Ovarian Cancer

Celsion Reports Translational Research Data From Its Phase 1b Study Of GEN-1 Immunotherapy In Recurrent Ovarian Cancer

Treatment with GEN-1 Results in Sustained, Targeted Production of Immunologically Active IL-12

Celsion Receives CFDA Approval To Conduct The OPTIMA Study In China

Celsion Receives CFDA Approval To Conduct The OPTIMA Study In China

25 Additional Clinical Sites To Be Added To Global Pivotal Phase III Study For The Treatment of Primary Liver Cancer

Celsion Announces Presentation Of DIGNITY Phase I/II ThermoDox® Data At The 2015 San Antonio Breast Cancer Symposium

Celsion Announces Presentation Of DIGNITY Phase I/II ThermoDox® Data At The 2015 San Antonio Breast Cancer Symposium

Local Responses Observed in over 60% of Evaluable Recurrent Chest Wall Breast Cancer Patients

Insider Trading Alert - BDX, CLSN And ACTG Traded By Insiders

Insider Trading Alert - BDX, CLSN And ACTG Traded By Insiders

Stocks with insider trader activity include BDX, CLSN and ACTG

Celsion Corporation Announces Dual Listing On The Tel Aviv Stock Exchange

Celsion Corporation Announces Dual Listing On The Tel Aviv Stock Exchange

Common Stock is currently listed on NASDAQ Capital Market and will also be listed on the Tel Aviv Stock Exchange (TASE)

Celsion Corporation Names Edwin De Wit, M.D. As Senior Vice President And Head Of Medical, Europe

Celsion Corporation Names Edwin De Wit, M.D. As Senior Vice President And Head Of Medical, Europe

Establishes Celsion GmbH, European Subsidiary, to Support Clinical Studies and Early Access Program in Europe

Celsion Announces Upcoming Presentations At The 2nd Asian Conference On Tumor Ablation On October 30-31, 2015

Celsion Announces Upcoming Presentations At The 2nd Asian Conference On Tumor Ablation On October 30-31, 2015

Two Oral Presentations from Leading Liver Cancer Experts will Highlight Curative Potential for ThermoDox® plus Optimized RFA in Intermediate HCC

Celsion Corporation Enrolls First Patient In The OVATION Study

Celsion Corporation Enrolls First Patient In The OVATION Study

First Line, Phase 1b Trial to Assess Immunotherapy Combining GEN-1 with Neo-Adjuvant Therapies in Newly Diagnosed Ovarian Cancer Patients

Celsion Completes Integration Of EGEN And Outlines Clinical Development Plan For GEN-1 IL-12 Immunotherapy Program

Celsion Completes Integration Of EGEN And Outlines Clinical Development Plan For GEN-1 IL-12 Immunotherapy Program

Company Strengthens Financial Profile with a 20 Percent Reduction in Headcount and a Leaner, More Efficient Product Development Organization

Celsion Announces Highlights From Symposium At The International Liver Cancer Association 2015 Annual Conference

Celsion Announces Highlights From Symposium At The International Liver Cancer Association 2015 Annual Conference

Presentations from Leading Liver Cancer Experts Highlight Curative Potential for ThermoDox® plus Optimized RFA (= 45 minutes) in Intermediate HCC